Epidermal Growth Factor Receptor EGFR gene copy number GCN correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ FISH and chromogenic in situ hybridization CISH analReportar como inadecuado




Epidermal Growth Factor Receptor EGFR gene copy number GCN correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ FISH and chromogenic in situ hybridization CISH anal - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 9:303

First Online: 27 August 2009Received: 16 May 2009Accepted: 27 August 2009DOI: 10.1186-1471-2407-9-303

Cite this article as: Scartozzi, M., Bearzi, I., Mandolesi, A. et al. BMC Cancer 2009 9: 303. doi:10.1186-1471-2407-9-303

Abstract

BackgroundK-RAS wild type colorectal tumors show an improved response rate to anti-EGFR monoclonal antibodies. Nevertheless 70% to 40% of these patients still does not seem to benefit from this therapeutic approach. FISH EGFR GCN has been previously demonstrated to correlate with clinical outcome of colorectal cancer treated with anti-EGFR monoclonal antibodies. CISH also seemed able to provide accurate EGFR GCN information with the advantage of a simpler and reproducible technique involving immunohistochemistry and light microscopy. Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab.

MethodsPatients with advanced K-RAS wild-type, colorectal cancer receiving irinotecan-cetuximab after failure of irinotecan-based chemotherapy were eligible.

A cut-off value for EGFR GCN of 2.6 and 2.12 for FISH and CISH respectively was derived from ROC curve analysis.

ResultsForty-four patients were available for analysis. We observed a partial remission in 9 60% and 2 9% cases with a FISH EGFR GCN ≥ 2.6 and < 2.6 respectively p = 0.002 and in 10 36% and 1 6% cases with a CISH EGFR GCN ≥ 2.12 and < 2.12 respectively p = 0.03. Median TTP was 7.7 and 6.4 months in patients showing increased FISH and CISH EGFR GCN whereas it was 2.9 and 3.1 months in those with low FISH and CISH EGFR GCN p = 0.04 and 0.02 respectively.

ConclusionFISH and CISH EGFR GCN may both represent effective tools for a further patients selection in K-RAS wild-type colorectal cancer treated with cetuximab.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-9-303 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Mario Scartozzi - Italo Bearzi - Alessandra Mandolesi - Chiara Pierantoni - Fotios Loupakis - Alberto Zaniboni - Francesca 

Fuente: https://link.springer.com/







Documentos relacionados